Nontuberculous Mycobacterial Infection in Cystic Fibrosis: Treatment Recommendations
A multidisciplinary team discussed exploring the management options for nontuberculous mycobacterial infection in patients with cystic fibrosis.
Obstructive Lung Disease
Differences in BAL Surveillance of Preschool Children With Cystic Fibrosis
Significant differences have been observed from bronchoalveolar lavage surveillance conducted among preschool children with cystic fibrosis, according to their country of residence.
Diversity of Mycobacterium abscessus Subclones in Pediatric Cystic Fibrosis
Sputum isolates of Mycobacterium abscessus may not reflect a patient’s full bacterial diversity.
Controlling Antibiotic Adverse Drug Reactions in Cystic Fibrosis
The majority of patients with cystic fibrosis experience at least 1 antibiotic adverse drug reaction.
Long-Term Azithromycin Reduced Need for IV Antibiotics in Cystic Fibrosis
Treatment with azithromycin during a 5-year period was associated with reductions in the use of intravenous antibiotics and pulmonary exacerbations in children with cystic fibrosis.
Elexacaftor-Tezacaftor-Ivacaftor Efficacious for Cystic Fibrosis
The percentage of FEV1 higher was at 4 weeks and through 24 weeks with treatment vs placebo.
FDA Approves Triple Combination Therapy for Cystic Fibrosis
The FDA has approved Trikafta for the treatment of patients aged 12 years and older with cystic fibrosis.
Aspergillosis, ABPA-Related Hospitalizations in Cystic Fibrosis Confer Worse Outcomes
Nearly one-third of patients with cystic fibrosis-related hospitalizations have aspergillosis, which is associated with worse outcomes.
Lumacaftor-Ivacaftor Improves Lung Function in Cystic Fibrosis After 1 Year
After one year of therapy, patients had improved lung function, increased BMI, and a reduced need for intravenous antibiotics.
New Clinical Tool Predicts 1- and 2-Year Mortality in Cystic Fibrosis
A novel clinical tool has been developed that uses patients’ overall health status and the risk for intermittent shock events to predict 1- and 2-year mortality in cystic fibrosis.
Next post in Obstructive Lung Disease
